 | Douglas E PetersonSchool of Dental Medicine & Neag Comprehensive Cancer Center, UConn Health, Farmington, CT. | Section of Oral Medicine, Department of Oral Health and Diagnostic Sciences, ... |
KOL Resume for Douglas E Peterson (oral mucositis, ulceration, stomatitis oral mucositis, mucositis, oral, stomatitis, ulcerative)
| Year | |
|---|---|
| 2021 | School of Dental Medicine & Neag Comprehensive Cancer Center, UConn Health, Farmington, CT. |
| 2020 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, UConn Health, Farmington, CT, USA |
| 2019 | Section of Oral Medicine, Department of Oral Health & Diagnostic Sciences, School of Dental Medicine & Neag Comprehensive Cancer Center, UConn Health, Farmington, CT. Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, UConn Health, Farmington, CT 06030, USA;, (B.-Y.H.);, (L.C.);, (A.T.);, (D.E.P.) UConn Health, University of Connecticut Health Center, Farmington, CT University of Connecticut School of Dental Medicine, Farmington, Connecticut |
| 2018 | Professor, Dept. of Oral Health and Diagnostic Sciences, School of Dental Medicine, UConn Health, Farmington, Connecticut, USA Neag Comprehensive Cancer Center, UConn Health |
| 2016 | School of Dental Medicine and Neag Comprehensive Cancer Center, UConn Health, Farmington, Connecticut |
| 2015 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Program in Head and Neck Cancer and Oral Oncology Program, Neag Comprehensive Cancer Center, UConn Health, Farmington, USA |
| 2014 | School of Dental Medicine, University of Connecticut Health Center, Farmington, Connecticut |
| 2013 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine and Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT, USA |
| 2012 | Section of Oral Medicine, Department of Oral Health & Diagnostic Sciences, School of Dental Medicine and Program in Head & Neck Cancer and Oral Oncology, Neag Comprehensive Cancer Center, University of Connecticut Health Center, 06030-1605, Farmington, CT, USA From the Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT; University of Adelaide, Adelaide, Australia; Harvard School of Dental Medicine, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, and Biomodels, LLC, Boston, MA. |
| 2011 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Program in Head & Neck Cancer and Oral Oncology Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, Connecticut, USA Editors Section of Oral Medicine, University of Connecticut School of Dental Medicine, Farmington, CT |
| 2010 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Program in Head and Neck Cancer and Oral Oncology, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, USA |
| 2009 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Head and Neck/Oral Oncology Program, Neag Comprehensive Cancer Center, Farmington, USA Authors' Affiliations: University of Delaware, Newark (Dr Brown); University of Maryland, Baltimore (Dr McGuire); University of Connecticut, Farmington (Dr Peterson); University of Utah, Salt Lake City (Drs Beck and Mooney); and University of North Carolina-Greensboro, Greensboro (Dr Dudley). |
| 2008 | Head and Neck/Oral Oncology Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center MC 1605, 263 Farmington Avenue, Farmington, CT 06030, USA |
| 2007 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, and Head & Neck/Oral Oncology Program, Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, Connecticut |
| 2006 | Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, Neag Comprehensive Cancer Center, University of Connecticut Health Center, 06030-1605, Farmington, CT, USA |
| 2005 | Cancer Center, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA Department of Oral Health and Diagnostic Sciences, School of Dental Medicine, University of Connecticut Health Center, Farmington, Connecticut |
| 2004 | Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030-1605, USA. |
| 2003 | Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington, CT 06030-1605, USA |
| 2002 | Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut, Farmington, Connecticut, U.S.A. |
| 2001 | School of Oral Medicine, Department of Oral Diagnosis, University of Connecticut Health Center, Farmington, Connecticut |
| 2000 | Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington, CT 06030–1605, USA, US |
| 1999 | Vancouver Hospital and Health Sciences Centre, British Columbia Cancer Centre 600 W 10th Ave Vancouver, BC V5Z 4E6 Canada Bone Marrow Transplant Program and Department of Radiation Oncology, University of Connecticut Health Center, School of Dental Medicine, Farmington, Connecticut Fred Hutchison Cancer Research Center and University of Washington Seattle, WA |
| 1997 | Division of Oral Medicine, Department of Oral Diagnosis, Farmington, CO, USA Department of Oral Diagnosis, University of Connecticut Dental School, Farmington, CT 06032 |
| 1996 | Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington, Connecticut, U.S.A. |
| 1995 | Division of Oral Medicine, Department of Oral Diagnosis, University of Connecticut School of Dental Medicine, Farmington, Connecticut |
| 1994 | School of Dental Medicine, University of Connecticut Health Center, Farmington. |
| 1993 | University of Connecticut Health Center Farmington, Conn. USA |
| 1992 | Department of Oral Diagnosis, School of Dental Medicine, University of Connecticut Health Center, Farmington 06030-1605. From the School of Dental Medicine, University of Connecticut Health Center, Farmington, Connecticut. |
| 1991 | Department of Oral Diagnosis, University of Maryland Dental School, Baltimore, Maryland Johns Hopkins University School of Medicine Baltimore, Md., USA |
| 1990 | Department of Oral Diagnosis, Dental School, University of Maryland, Baltimore. The Fred Hutchinson Cancer Research Center Seattle, Wash., USA |
| 1989 | Baltimore College of Dental Surgery, Dental School, Baltimore, MDUSA |
| 1988 | Program in Oncology, University of Maryland Cancer Center; and Department of Oral Diagnosis, Baltimore College of Dental Surgery, Dental School, University of Maryland at Baltimore, Baltimore, MD 21201. |
| 1986 | Dr. Peterson is associate professor, department of oral diagnosis, and associate professor, program in oncology, Baltimore College of Dental Surgery, Dental School, University of Maryland at Baltimore, 666 W Baltimore St, Baltimore, 21201. Fred Hutchinson Cancer Research Center, Seattle, Washington University of Maryland Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland |
| 1983 | Department of University of Maryland Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland |
| 1982 | Department of Oral Diagnosis, Baltimore College of Dental Surgery, Dental School, University of Maryland at Baltimore, Baltimore, Maryland, 21201 USA |
| 1981 | Baltimore College of Dental Surgery, University of Maryland School of Dentistry Baltimore, Md. USA |
| 1979 | School of Dentistry, University of Maryland Baltimore, Md., USA |
Prominent publications by Douglas E Peterson
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
[ PUBLICATION ]
BACKGROUND: Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis.
METHODS: A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 ...
| Known for Cancer Therapy | Clinical Practice Guidelines | Published Criteria | Mascc Isoo | Hyperbaric Oxygenation |
Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy
[ PUBLICATION ]
PurposeThis systematic review analyzed the strength of the literature and defined clinical practice guidelines for the use of oral cryotherapy for the prevention and/or treatment of oral mucositis caused by cancer therapy.MethodsA systematic review on relevant oral cryotherapy studies indexed prior to 31 December 2010 was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) using ...
| Known for Oral Cryotherapy | Cancer Therapy | Suggestion Guideline | Highdose Melphalan | Mucositis Caused |
PURPOSE: To evaluate the efficiency of Helium-Neon (He-Ne) laser in the prevention of oral mucositis induced by high dose chemoradiotherapy before autologous bone marrow transplantation (BMT).
METHODS AND MATERIALS: Between 1993 and 1995, 30 consecutive patients receiving an autologous peripheral stem-cell or bone marrow transplant (BMT) after high dose chemoradiotherapy were randomized to possibly receive prophylactic laser to the oral mucosa after giving informed consent. Chemotherapy ...
| Known for Oral Mucositis | Bone Marrow | Parenteral Nutrition | Blind Randomized | Low Energy |
BACKGROUND: The current report presented 17 patients with cancer with bone metastases and 1 patient with osteopenia who received treatment with bisphosphonates and who subsequently developed osteonecrosis of the mandible and/or maxilla.
METHODS: The authors reviewed information on 18 patients who were referred to oral medicine or oral surgery specialists for evaluation and treatment of mandibular and/or maxillary bone necrosis from June 2002 to September 2004. To be included in the ...
| Known for Patients Cancer | Bisphosphonate Therapy | Osteonecrosis Mandible | Metastatic Disease | Maxillary Bone |
Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
[ PUBLICATION ]
PurposeTo update the 2013 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) clinical practice guidelines on oral cryotherapy for the management of oral mucositis (OM) caused by cancer therapies.MethodsA systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The evidence for each intervention for specific cancer treatment modalities was assigned a level of evidence (LoE). The findings were added to the database ...
| Known for Oral Cryotherapy | Practice Guidelines | Mascc Isoo | Cancer Therapies | Mucositis Study |
Using high throughput sequencing to explore the biodiversity in oral bacterial communities
[ PUBLICATION ]
High throughput sequencing of 16S ribosomal RNA gene amplicons is a cost-effective method for characterization of oral bacterial communities. However, before undertaking large-scale studies, it is necessary to understand the technique-associated limitations and intrinsic variability of the oral ecosystem. In this work we evaluated bias in species representation using an in vitro-assembled mock community of oral bacteria. We then characterized the bacterial communities in saliva and ...
| Known for Oral Bacteria | Throughput Sequencing | Analysis Rna | Mouth Mucosa | Streptococcus Mitis |
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study
[ PUBLICATION ]
GoalsOral mucositis can be a significant and dose-limiting complication of high-dose cancer therapy. Mucositis is a particularly severe problem in patients receiving myeloablative chemotherapy prior to bone marrow or hematopoetic stem cell transplant (HSCT). The cyclooxygenase (COX) pathway mediates tissue injury and pain through upregulation of pro-inflammatory prostaglandins, including prostaglandin E2 (PGE2) and prostacyclin (PGI2). The objective of this small (n = 3) pilot study was ...
| Known for Oral Mucositis | Cyclooxygenase Pathway | Proinflammatory Prostaglandins | Mucosal Injury | Inflammatory Mediators |
Helium‐neon laser effects on conditioning‐induced oral mucositis in bone marrow transplantation patients
[ PUBLICATION ]
BACKGROUND: Oral mucositis is a common complication of bone marrow transplantation (BMT) conditioning therapy. Sequelae consist of increased risk for infection, moderate to severe pain, compromised oral function, and bleeding. This study investigated helium-neon laser treatment for prevention of conditioning-induced oral mucositis in BMT patients. Patterns and severity of mucositis for specific conditioning drug regimens also were analyzed.
METHODS: Twenty patients received laser ...
| Known for Oral Mucositis | Marrow Transplantation | Neon Laser | Bmt Patients | Pain Severity |
Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis
[ PUBLICATION ]
BackgroundGastrointestinal mucosal injury (mucositis), commonly affecting the oral cavity, is a clinically significant yet incompletely understood complication of cancer chemotherapy. Although antineoplastic cytotoxicity constitutes the primary injury trigger, the interaction of oral microbial commensals with mucosal tissues could modify the response. It is not clear, however, whether chemotherapy and its associated treatments affect oral microbial communities disrupting the homeostatic ...
| Known for Oral Mucositis | Dysbiotic Shifts | Cancer Chemotherapy | Mucosal Tissues | Genera Streptococcus |
OBJECTIVE: Millions of patients worldwide are taking medications that alter hemostasis and decrease the risk for thromboembolic events. This systematic review is intended to provide recommendations regarding optimal management of such patients undergoing invasive dental procedures. The primary focus of this report is on warfarin therapy, although issues related to heparin and aspirin are briefly discussed because of the frequency with which they are encountered in dental practice.
STUDY ...
| Known for Dental Patients | Warfarin Therapy | Chronically Humans | Management Recommendations | Thromboembolic Events |
Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation.
[ PUBLICATION ]
PURPOSE: To explore the relationship between oral mucositis and selected clinical and economic outcomes in blood and marrow transplant patients.
PATIENTS AND METHODS: Subjects consisted of 92 transplant patients from eight centers who participated in a multinational pilot study of a new oral mucositis scoring system (Oral Mucositis Assessment Scale [OMAS]). In the pilot study, patients were evaluated for erythema and ulceration/pseudomembrane formation beginning on the first day of ...
| Known for Oral Mucositis | Economic Outcomes | Hematopoietic Stem | Cell Transplantation | Parenteral Nutrition |
Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study.
[ PUBLICATION ]
The purposes of this prospective, repeated-measures descriptive pilot study were to describe patterns of acute oral pain and mucositis in patients receiving a bone marrow transplant or high-dose chemotherapy for leukemia, and to test procedures and instruments before initiating a larger intervention study. A nonprobability, purposive selection process was used to enroll 18 patients admitted to two acute care inpatient hospital units for bone marrow transplantation or leukemia therapy at ...
| Known for Oral Pain | Bone Marrow | Mucositis Patients | Erythema Ulceration | Highdose Chemotherapy |
Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Food and Drug Administration and other regulatory agencies in Europe and Australia. These changes necessitate an updated review of the literature and guidelines. Panel members reviewed the biomedical ...
| Known for Treatment Mucositis | Practice Guidelines | Radiation Proctitis | Mucosal Injury | Biomedical Literature |
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.
[ PUBLICATION ]
PURPOSE: To provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer.
METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. Guideline development involved a systematic review of the literature and a formal consensus process. ...
| Known for Jaw Mronj | Prevention Management | Medicationrelated Osteonecrosis | Multinational Association | Asco Clinical |
Douglas E Peterson: Influence Statistics
| Concept | World rank |
|---|---|
| catheterized bmt recipients | #1 |
| bone‐modifying agent | #1 |
| mucositis dysbiotic | #1 |
| mouth distress | #1 |
| salivary compromise chapter | #1 |
| defined midpoint | #1 |
| regimen ticarcillin disodium | #1 |
| saforis placebo | #1 |
| effects sanguinarium | #1 |
| gastrointestinal disease endocrinopathies | #1 |
| midchemotherapy prechemotherapy | #1 |
| dental extraction patient | #1 |
| renal marrow recipients | #1 |
| myelosuppressed cancer | #1 |
| medical dental testing | #1 |
| carryover treatment cycle | #1 |
| chemotherapy agents patterns | #1 |
| complex symptom experience | #1 |
| mucositis bone | #1 |
| oral ecology patients | #1 |
| primary injury trigger | #1 |
| erythema buccal mucosa | #1 |
| simple dental extractions | #1 |
| mucositis published | #1 |
| asymptomatic periodontal disease | #1 |
| lowgrade osteomyelitis | #1 |
| patterns sore | #1 |
| saforis glutamine | #1 |
| stomatitis telemedicine | #1 |
| unanswered questions multitude | #1 |
| oral infection patients | #1 |
| admission acute exacerbations | #1 |
| literature divergent data | #1 |
| condition herpes | #1 |
| mucosal periapical loci | #1 |
| isoo asco | #1 |
| divergent oral environments | #1 |
| molecularly targeted prevention | #1 |
| unusual instance | #1 |
| oral tissues majority | #1 |
| economic costs management | #1 |
| treatment cycle subjects | #1 |
| staphylococcus supragingival | #1 |
| cultivation malassezia | #1 |
Open the FULL List in Excel | |
Key People For Oral Mucositis
Douglas E Peterson:Expert Impact
Concepts for whichDouglas E Petersonhas direct influence:Oral mucositis, Oral medicine, Oral complications, Aspergillus sinusitis, Cancer therapy, Oral cryotherapy, Cancer therapies, Oral candidiasis.
Douglas E Peterson:KOL impact
Concepts related to the work of other authors for whichfor which Douglas E Peterson has influence:Oral mucositis, Radiation therapy, Neck cancer, Stem cell, Multiple myeloma, Host disease, Quality life.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |